Ascertainment rate of novel coronavirus disease (COVID-19) in Japan
Related Experiment Video
Updated: Sep 28, 2025

Author Spotlight: Advancements in Multiplex Detection of Respiratory Viruses
Published on: November 10, 2023
Ryosuke Omori1, Kenji Mizumoto2, Hiroshi Nishiura3
1Research Center for Zoonosis Control, Hokkaido University, Kita-ku, Sapporo-shi, Hokkaido 001-0020, Japan.
Objective:
To estimate the ascertainment rate of novel coronavirus disease (COVID-19).
Methods:
The epidemiological dataset of confirmed cases with COVID-19 in Japan as of February 28, 2020 was analyzed. A statistical model was constructed to describe the heterogeneity of the reporting rate by age and severity. We estimated the number of severe and non-severe cases, accounting for under-ascertainment.
Results:
The ascertainment rate of non-severe cases was estimated at 0.44 (95% confidence interval 0.37-0.50), indicating that the unbiased number of non-severe cases would be more than twice the reported count.
Conclusions:
Severe cases are twice as likely to be diagnosed and reported when compared to other cases. Considering that reported cases are usually dominated by non-severe cases, the adjusted total number of cases is also approximately double the observed count. This finding is critical in interpreting the reported data, and it is advised that the mild case data for COVID-19 should always be interpreted as under-ascertained [Au?1].
More Related Videos
Related Concept Videos
Pie Chart
In a pie chart, the central angle, the arc length of each slice, and the area are directly proportional to the quantity or percentage it represents. Some real-world examples that can be depicted using pie charts include marks obtained by students...
Prevalence and Incidence
Prevalence indicates the proportion of individuals in a population who have a specific disease or health...
Pareto Chart
The Pareto chart is named after the Italian economist Vilfredo Pareto, who described the Pareto...
Principles of Disease Surveillance
Hazard Ratio
For example, in a clinical trial...
Relative Risk

